Hanh Thi My Nguyen

Ms. Hanh Thi My Nguyen

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
NVNam Vo
Nam Vo
HNHanh Thi My Nguyen
Hanh Thi My Nguyen
NPNhat Manh Phan
Nhat Manh Phan
Hương Lai PhạmHương Lai Phạm
Hương Lai Phạm
TBTan Trong Bui
Tan Trong Bui
TBTien Bui
Tien Bui
Background/Objectives: Dyslipidemia is becoming a significant economic healthcare burden in low- to middle-income countries (LMICs) due to its role in heightening cardiovascular-related mortality. Statins are the first-line treatment for reducing LDL-C levels, thereby minimizing direct costs associated with cardiovascular disease management, with pitavastatin being the newest generation of statins. This research conducts a cost-utility analysis of pitavastatin to determine the economic benefit in Vietnam. Methods: A decision tree model was developed to compare the rate of LDL-C-controlled patients within a 12-week time horizon among patients treated with pitavastatin, atorvastatin, and rosuvastatin. The primary outcome was the Incremental Cost-Effectiveness Ratio (ICER), measured from the healthcare system perspective. Effectiveness was evaluated in terms of quality-adjusted life years (QALYs), using an annual discount rate of 3%. A one-way sensitivity analysis was performed to identify the key input parameters that most influenced the ICER outcomes. Results: Pitavastatin was cost-effective compared to atorvastatin but dominated by rosuvastatin after 3 months. Although pitavastatin gained less QALY than atorvastatin, the ICER was 6,254,017 VND/ QALY, well below Vietnam’s 2024 Willing-to-Pay. Drug cost had the most significant impact on ICERs. Conclusions: Pitavastatin represents an economical short-term alternative to atorvastatin, particularly in resource-constrained settings. Further evaluations over longer horizons are warranted to assess long-term cost-effectiveness.

1 October 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
NVNam Vo
Nam Vo
HNHanh Thi My Nguyen
Hanh Thi My Nguyen
NPNhat Manh Phan
Nhat Manh Phan
Hương Lai PhạmHương Lai Phạm
Hương Lai Phạm
TBTan Trong Bui
Tan Trong Bui
TBTien Bui
Tien Bui
Background/Objectives: Dyslipidemia is becoming a significant economic healthcare burden in low- to middle-income countries (LMICs) due to its role in heightening cardiovascular-related mortality. Statins are the first-line treatment for reducing LDL-C levels, thereby minimizing direct costs associated with cardiovascular disease management, with pitavastatin being of the newest generation of statins. This research work conducted a cost-utility analysis of pitavastatin to determine the economic benefit in Vietnam. Methods: A decision tree model was developed to compare the rate of LDL-C controlled patients over a lifetime horizon among patients treated with pitavastatin, atorvastatin, and rosuvastatin. The primary outcome was the incremental cost-effectiveness ratio (ICER), measured from the healthcare system perspective. Effectiveness was evaluated in terms of quality-adjusted life years (QALYs), using an annual discount rate of 3%. A one-way sensitivity analysis was performed to identify the key input parameters that most influenced the ICER outcomes. Results: Pitavastatin was cost-effective compared to atorvastatin but was dominated by rosuvastatin. Although pitavastatin gained fewer QALYs than atorvastatin, the ICER was 195,403,312 VND/QALY, well below Vietnam’s 2024 willingness-to-pay. Drug cost had the most significant impact on ICERs. Conclusions: Pitavastatin represents an economical short-term alternative to atorvastatin, particularly in resource-constrained settings.